论文部分内容阅读
目的:探讨Plk1及Cyclin Bl在宫颈鳞癌中的表达及其与临床病理因素之间的关系。方法:利用组织芯片技术,结合免疫组化Elivision方法对88例宫颈鳞状细胞癌、20例宫颈上皮内瘤变(CIN)、20例正常宫颈组织中Plkl和Cyclin Bl表达情况进行检测。结果:Plkl在宫颈鳞癌、CIN中的表达阳性率分别为72.7%、55.0%,明显高于正常宫颈组织10.0%,差异有统计学意义(P<0.01),但前两者之间差异无统计学意义(P>0.05)。Cyclin Bl在宫颈鳞癌中的表达阳性率54.5%,明显高于CIN 30.0%和正常宫颈组织10.0%,差异有统计学意义(P<0.01)。Plk1的表达与宫颈鳞癌淋巴结转移相关(P<0.05),Cyclin B1的表达与宫颈鳞癌浸润深度相关(P<0.05),且Plkl和Cyclin Bl在宫颈鳞癌中的表达呈正相关(rs=0.261,P=0.014)。结论:Plkl和Cyclin Bl的表达与宫颈鳞癌的发生发展、浸润深度和转移相关,两者联合有可能成为宫颈鳞癌临床治疗的新靶点。
Objective: To investigate the expression of Plk1 and Cyclin B1 in cervical squamous cell carcinoma and its relationship with clinicopathological factors. Methods: The expression of Plkl and Cyclin Bl in 88 cases of cervical squamous cell carcinoma, 20 cases of cervical intraepithelial neoplasia (CIN) and 20 cases of normal cervical tissue were detected by tissue chip technique combined with Elivision immunohistochemistry. Results: The positive rates of Plkl expression in cervical squamous cell carcinoma and CIN were 72.7% and 55.0%, respectively, which were significantly higher than those in normal cervical tissue (P <0.01), but there was no significant difference between the two groups Statistical significance (P> 0.05). The positive rate of Cyclin B1 expression in cervical squamous cell carcinoma was 54.5%, which was significantly higher than that of CIN 30.0% and normal cervical tissue 10.0%, the difference was statistically significant (P <0.01). The expression of Plk1 was correlated with lymph node metastasis of cervical squamous cell carcinoma (P <0.05). The expression of Cyclin B1 was correlated with the depth of invasion of cervical squamous cell carcinoma (P <0.05), and the positive expression of Plkl and Cyclin Bl in cervical squamous cell carcinoma (rs = 0.261, P = 0.014). Conclusions: The expressions of Plkl and Cyclin Bl are correlated with the development of cervical squamous cell carcinoma, the depth of invasion and the metastasis of cervical squamous cell carcinoma. The combination of Plkl and Cyclin Bl may become a new target for the clinical treatment of cervical squamous cell carcinoma.